Austedo
Registration timeline
The following table summarises the key steps and dates for this application.
| Description | Date |
|---|---|
| Submission dossier accepted and first round evaluation commenced | 30 March 2020 |
| First round evaluation completed | 1 September 2020 |
| Sponsor provides responses on questions raised in first round evaluation | 2 November 2020 |
| Second round evaluation completed | 29 April 2021 |
| Delegate's overall benefit-risk assessment and request for Advisory Committee advice | 2 March 2021 |
| Sponsor's pre-Advisory Committee response | 16 March 2021 |
| Advisory Committee meeting | 8 and 9 April 2021 |
| Registration decision (Outcome) | 26 May 2021 |
| Completion of administrative activities and registration on ARTG | 2 June 2021 |
| Number of working days from submission dossier acceptance to registration decision* | 190 |
*Statutory timeframe for standard applications is 255 working days
The dose of Austedo is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. When first prescribed to patients who are not being switched from tetrabenazine (a related vesicular monoamine transporter type 2 (VMAT2) inhibitor), the recommended starting dose of Austedo is 6 mg administered orally once daily for patients with Huntington’s disease and 12 mg per day (6 mg twice daily) for patients with tardive dyskinesia.
For further information refer to the Product Information.
Austedo (deutetrabenazine) was approved for the following therapeutic use:
Austedo is indicated for the treatment of:
- chorea associated with Huntington's disease
- tardive dyskinesia in adults
- Austedo (deutetrabenazine) is to be included in the Black Triangle Scheme. The Product Information and Consumer Medicines Information for Austedo must include the black triangle symbol and mandatory accompanying text for five years, which starts from the date that the sponsor notifies the TGA of supply of the product.
- The deutetrabenazine risk management plan (RMP) (version 1.1, dated 23 October 2020, data lock point 15 September 2020), included with submission PM-2020-00739-1-1, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.
An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs).
Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be submitted to TGA no later than 15 calendar months after the date of the approval letter. The subsequent reports must be submitted no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of the approval letter. The annual submission may be made up of two PSURs each covering six months. If the sponsor wishes, the six monthly reports may be submitted separately as they become available.
If the product is approved in the European Union (EU) during the three years period, reports can be provided in line with the published list of EU reference dates no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of the approval letter.
The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's Guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report (Rev 1), Part VII.B Structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration. Each report must have been prepared within ninety calendar days of the data lock point for that report.